J
Johannes Schröder
Researcher at Heidelberg University
Publications - 284
Citations - 13056
Johannes Schröder is an academic researcher from Heidelberg University. The author has contributed to research in topics: Dementia & Alzheimer's disease. The author has an hindex of 56, co-authored 278 publications receiving 11850 citations. Previous affiliations of Johannes Schröder include University Hospital Heidelberg & Pontifical Catholic University of Chile.
Papers
More filters
Journal ArticleDOI
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Niklas Mattsson,Henrik Zetterberg,Oskar Hansson,Niels Andreasen,Lucilla Parnetti,Michael Jonsson,Sanna-Kaisa Herukka,Wiesje M. van der Flier,Marinus A. Blankenstein,Michael Ewers,Kenneth Rich,Elmar Kaiser,Marcel M. Verbeek,Magda Tsolaki,Ezra Mulugeta,Erik Rosén,Dag Aarsland,Pieter Jelle Visser,Johannes Schröder,Jan Marcusson,Mony J. de Leon,Harald Hampel,Philip Scheltens,Tuula Pirttilä,Anders Wallin,Maria Eriksdotter Jönhagen,Lennart Minthon,Bengt Winblad,Kaj Blennow +28 more
TL;DR: This multicenter study found that CSF Abeta42, T-t Tau, and P-tau identify incipient AD with good accuracy, but less accurately than reported from single-center studies.
Journal ArticleDOI
Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET
Karl Herholz,Eric Salmon,Daniela Perani,Jean-Claude Baron,Vjera Holthoff,Lutz Frölich,Peter Schönknecht,Kengo Ito,R. Mielke,Elke Kalbe,Gerhard Zündorf,Xavier Delbeuck,O. Pelati,Davide Anchisi,Ferruccio Fazio,Nacer Kerrouche,Béatrice Desgranges,Francis Eustache,Bettina Beuthien-Baumann,C. Menzel,Johannes Schröder,Takashi Kato,Yutaka Arahata,Marcus Henze,W.-D. Heiss +24 more
TL;DR: A new diagnostic indicator of FDG PET scan abnormality, based on age-adjusted t statistics and an automated voxel-based procedure, is presented and validated in a large data set comprising 110 normal controls and 395 patients with probable Alzheimer's disease (AD) that were studied in eight participating centers as discussed by the authors.
Journal ArticleDOI
Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay
Nobuo Ida,Tobias Hartmann,Johannes Pantel,Johannes Schröder,Rainer Zerfass,Hans Förstl,Rupert Sandbrink,Colin L. Masters,Konrad Beyreuther +8 more
TL;DR: It is found that CSF βA4 1-42 level is lower in AD patients compared with non-demented controls, although there was a significant overlap between the groups.
Journal ArticleDOI
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Niklas Mattsson,Ulf Andreasson,Staffan Persson,Hiroyuki Arai,Sat Dev Batish,Sergio Bernardini,Luisella Bocchio-Chiavetto,Marinus A. Blankenstein,Maria Berrocal Carrillo,Sonia Chalbot,Els Coart,Davide Chiasserini,Neal Cutler,Gunilla Dahlfors,Stefan Duller,Anne M. Fagan,Orestes Vicente Forlenza,Giovanni B. Frisoni,Douglas Galasko,Daniela Galimberti,Harald Hampel,Aase Handberg,Michael T. Heneka,Adrianna Z. Herskovits,Sanna-Kaisa Herukka,David M. Holtzman,Christian Humpel,Bradley T. Hyman,Khalid Iqbal,Mathias Jucker,Stephan A. Kaeser,Elmar Kaiser,Elisabeth Kapaki,Daniel Kidd,Péter Klivényi,Cindy Soendersoe Knudsen,Markus P. Kummer,James Lui,Albert Lladó,Piotr Lewczuk,Qiao-Xin Li,Ralph N. Martins,Colin L. Masters,John McAuliffe,Marc Mercken,Abhay Moghekar,José Luis Molinuevo,Thomas J. Montine,William Nowatzke,Richard O'Brien,Markus Otto,George P. Paraskevas,Lucilla Parnetti,Ronald C. Petersen,David Prvulovic,Herman P M de Reus,Robert A. Rissman,Elio Scarpini,Alessandro Stefani,Hilkka Soininen,Johannes Schröder,Leslie M. Shaw,Anders Skinningsrud,Brith Skrogstad,Annette Spreer,Leda Leme Talib,Charlotte E. Teunissen,John Q. Trojanowski,Hayrettin Tumani,Robert M. Umek,Bianca Van Broeck,Hugo Vanderstichele,László Vécsei,Marcel M. Verbeek,Manfred Windisch,Jing Zhang,Henrik Zetterberg,Kaj Blennow +77 more
TL;DR: The cerebrospinal fluid biomarkers amyloid β (Aβ)‐42, total‐Tau (T‐tau), and phosphorylated‐t Tau (P‐tAU) demonstrate good diagnostic accuracy for Alzheimer's disease (AD), but there are large variations in biomarker measurements between studies, and between and within laboratories.
Journal ArticleDOI
CSF biomarker variability in the Alzheimer's Association quality control program
Niklas Mattsson,Niklas Mattsson,Ulf Andreasson,Staffan Persson,Maria C. Carrillo,Steven J. Collins,Sonia Chalbot,Neal Cutler,Diane Dufour-Rainfray,Anne M. Fagan,Niels H. H. Heegaard,Ging-Yuek Robin Hsiung,Bradley T. Hyman,Khalid Iqbal,D. Richard Lachno,Alberto Lleó,Piotr Lewczuk,José Luis Molinuevo,Piero Parchi,Axel Regeniter,Robert A. Rissman,Hanna Rosenmann,Giuseppe Sancesario,Johannes Schröder,Leslie M. Shaw,Charlotte E. Teunissen,John Q. Trojanowski,Hugo Vanderstichele,Manu Vandijck,Marcel M. Verbeek,Henrik Zetterberg,Henrik Zetterberg,Kaj Blennow,Stephan A. Käser,Aladro José A. Rojo,Marilyn S. Albert,Daniel Alcolea,Anna Antonell,Hiroyuki Arai,Silvana Archetti,Eva Arkblad,Inês Baldeiras,Ales Bartos,Dev Batish,Aurélie Bedel,Daniele Bentue-Ferrer,Flora Berisha,Sergio Bernardini,Marinus A. Blankenstein,Olivier Bousiges,Michael C. Camuso,Maria Berrocal Carrillo,Tiziana Casoli,Sebastiano Cavallaro,Odete A. da Cruz e Silva,Isabelle Cuvelier,Odile Delaroche,Roy B. Dyer,Sebastiaan Engelborghs,Anne Fogli,Orestes Vicente Forlenza,Nick C. Fox,Giovanni B. Frisoni,Daniela Galimberti,Elisabetta Galloni,Silvana Gritti,Karen H. Gylys,Harald Hampel,Sabine Haustein,Theresa Heath,Michael T. Heneka,Sanna-Kaisa Herukka,David M. Holtzman,Christian Humpel,Takeshi Iwatsubo,Claude Jardel,Mathias Jucker,Elisabeth Kapaki,Daniel Kidd,Péter Klivényi,Ryozo Kuwano,Foudil Lamari,Jean-Louis Laplanche,Jordan Laser,Sylvian Lehmann,Qiao-Xin Li,Walter Maetzler,Catherine Malaplate-Armand,Ralph Martin,Robert Martone,Colin L. Masters,Marc Mercken,Jose Luis Molinuevo,T. J. Montine,William Nowatzke,Markus Otto,Xavier Parent,Lucilla Parnetti,Ronald C. Petersen,Koen Poesen,Isabelle Quadrio,Muriel Quillard,Vara Luis Rello,Zdenek Rohan,Christin Sisowath,Anders Skinningsrud,Holly Soares,Hilkka Soininen,Knudsen Cindy Søndersø,Annette Spreer,Silvia Suardi,C.E. Teunissen,Robert M. Umek,Bianca Van Broeck,Rik Vandenberghe,László Vécsei,M.M. Verbeek,Igor Vostiar,Manfred Windisch +118 more
TL;DR: The cerebrospinal fluid biomarkers amyloid beta 1–42, total tau, and phosphorylated tau are used increasingly for Alzheimer's disease research and patient management, but there are large variations in biomarker measurements among and within laboratories.